Receptor, Serotonin, 5-HT2C - Agonists
Research News and Information

Monday, November 23, 2009

In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.

20 Aug 2009 Control of the mesoaccumbens dopamine (DA) pathway by central serotonin(2C) receptors (5-HT(2C)Rs) involves different 5-HT(2C)R populations located within multiple brain areas. Here, using in vivo microdialysis in halothane-anesthetized rats, we ... Read more...

Implication of the 5-HT2A and 5-HT2C (but not 5HT1A) receptors located within the periaqueductal gray in the elevated plus-maze test-retest paradigm in mice.

17 Jul 2009 A single exposure to the elevated plus-maze test (EPM) increases open arms avoidance and reduces or abolishes the anxiolytic-like effect of benzodiazepines assessed during a second trial, a phenomenon defined as "one-trial tolerance" (OTT). It has ... Read more...

Serotonin 5-HT2C receptor-independent expression of hypothalamic NOR1, a novel modulator of food intake and energy balance, in mice.

8 Jun 2009 NOR1, Nur77 and Nurr1 are orphan nuclear receptors and members of the NR4A subfamily. Here, we report that the expression of hypothalamic NOR1 was remarkably decreased in mildly obese beta-endorphin-deficient mice and obese db/db mice with the ... Read more...

Latest indexed articles for 'Receptor, Serotonin, 5-HT2C - Agonists'

These are the very latest articles for this heading:

• In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. 20 Aug 2009
• Implication of the 5-HT2A and 5-HT2C (but not 5HT1A) receptors located within the periaqueductal gray in the elevated plus-maze test-retest paradigm in mice. 17 Jul 2009
• Serotonin 5-HT2C receptor-independent expression of hypothalamic NOR1, a novel modulator of food intake and energy balance, in mice. 8 Jun 2009
• 5-HT2C-like receptors in the brain of Xenopus laevis initiate sex-typical fictive vocalizations. 25 May 2009
• Identification of novel serotonin 2C receptor ligands by sequential virtual screening. 6 May 2009
• (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. May 2009
• Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action. 7 Apr 2009
• Synergistic actions of apomorphine and m-chlorophenylpiperazine on ejaculation, but not penile erection in rats. 30 Mar 2009
• 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. 23 Mar 2009
• 7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization. 19 Feb 2009
• Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT2C receptor agonists. 10 Feb 2009
• Reduced sensitivity to the locomotor-stimulant effects of cocaine is associated with increased sensitivity to its discriminative stimulus properties. 30 Jan 2009
• Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes. 30 Dec 2008
• Stimulation of basolateral amygdaloid serotonin 5-HT(2C) receptors promotes the induction of long-term potentiation in the dentate gyrus of anesthetized rats. 22 Dec 2008
• Subthalamic neurons show increased firing to 5-HT2C receptor activation in 6-hydroxydopamine-lesioned rats. 22 Dec 2008
• WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. 18 Dec 2008
• Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. 4 Dec 2008
• Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors. 3 Dec 2008
• Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin. 3 Dec 2008
• Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. 2 Dec 2008

See a longer list of these articles.

Technical information about 'Receptor, Serotonin, 5-HT2C'

Definition: A serotonin receptor subtype found primarily in the CENTRAL NERVOUS SYSTEM and the CHOROID PLEXUS. This receptor subtype is believed to mediate the anorectic action of SEROTONIN, while selective antagonists of the 5-HT2C receptor appear to induce ANXIETY. Several isoforms of this receptor subtype exist, due to adenine deaminase editing of the receptor mRNA.

Registry Number: 0

Descriptor UI: D044405

Alternative terms: Receptor, Serotonin, 5-HT2C; 5-HT2C Receptor; 5 HT2C Receptor; Receptor, 5-HT2C; 5-Hydroxytryptamine Type 2C Receptor; 5 Hydroxytryptamine Type 2C Receptor; Serotonin 2C Receptor; 2C Receptor, Serotonin; Receptor, Serotonin 2C; 5-Hydroxytryptamine Type 2C Receptors; 5 Hydroxytryptamine Type 2C Receptors; Receptor, 5-Hydroxytryptamine Type 2C; Receptor, 5 Hydroxytryptamine Type 2C; 5-HT(2C) Receptor;

Allowable Qualifiers: administration & dosage; analysis; antagonists & inhibitors; biosynthesis; blood; classification; deficiency; drug effects; genetics; history; immunology; isolation & purification; metabolism; physiology; radiation effects; therapeutic use; ultrastructure; chemistry; agonists;

Tree Number: D12.776.543.750.070.800.200.575; D12.776.543.750.100.800.200.200; D12.776.543.750.720.300.800.200.200;

History Note: 2004; use RECEPTOR, SEROTONIN, 5-HT2C (NM) 1994-2003